MiNK Therapeutics Reports Clinical and Strategic Milestones and Second Quarter 2025 Results
NEW YORK, Aug. 14, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic, off-the-shelf invariant natural killer T (iNK...
What is the risk of dilution from future financing rounds, and how does it compare to the company's current equity structure?
How does the company's share price volatility compare to its historical volatility and the broader biotech index?
What is the impact of the reported sentiment score (70) on investor sentiment and short‑term trading volume?
28 days ago